Illumina, Inc. (NASDAQ:ILMN) Receives $128.15 Average Price Target from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN - Get Free Report) have received a consensus recommendation of "Hold" from the twenty-one analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $128.15.

Several research analysts have commented on the stock. JPMorgan Chase & Co. decreased their target price on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a report on Friday, May 9th. TD Cowen cut shares of Illumina from a "buy" rating to a "hold" rating and decreased their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Canaccord Genuity Group decreased their price target on shares of Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a report on Monday, May 12th. Barclays cut their price objective on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research report on Thursday, April 10th. Finally, Morgan Stanley dropped their price target on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th.

Insider Activity at Illumina

In other Illumina news, CFO Ankur Dhingra acquired 6,100 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were bought at an average cost of $81.21 per share, with a total value of $495,381.00. Following the completion of the transaction, the chief financial officer now directly owns 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This represents a 32.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Illumina

Several institutional investors have recently made changes to their positions in ILMN. Capital World Investors boosted its holdings in shares of Illumina by 408.6% in the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares during the period. Vanguard Group Inc. raised its position in shares of Illumina by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock worth $1,298,928,000 after acquiring an additional 558,243 shares in the last quarter. WCM Investment Management LLC increased its position in Illumina by 1.2% during the 1st quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock valued at $334,321,000 after buying an additional 49,156 shares in the last quarter. Corvex Management LP grew its stake in Illumina by 125.2% during the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company's stock valued at $303,841,000 after purchasing an additional 2,129,449 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Illumina by 0.8% during the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock valued at $454,617,000 after purchasing an additional 27,618 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Price Performance

Shares of NASDAQ:ILMN traded down $0.15 during trading hours on Friday, hitting $84.28. 1,609,920 shares of the company's stock traded hands, compared to its average volume of 2,326,709. Illumina has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company's fifty day simple moving average is $77.86 and its two-hundred day simple moving average is $107.09. The company has a market cap of $13.34 billion, a price-to-earnings ratio of -10.97, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the firm posted $0.98 EPS. The business's revenue for the quarter was down 1.4% on a year-over-year basis. As a group, equities analysts anticipate that Illumina will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.